Indication

Germline BRCA-mutated metastatic pancreatic adenocarcinoma

Germline BRCA-mutated metastatic pancreatic adenocarcinoma is an advanced stage IV malignancy arising from the exocrine ductal epithelial cells of the pancreas that has disseminated to distant anatomical sites. Read more about Germline BRCA-mutated metastatic pancreatic adenocarcinoma

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Germline BRCA-mutated metastatic pancreatic adenocarcinoma therapies.

Showing 1–1 of 1 drugs

LYNPARZA (olaparib)

ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR·EPITHELIAL OVARIAN CANCER·+5
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Germline BRCA-mutated metastatic pancreatic adenocarcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Germline BRCA-mutated metastatic pancreatic adenocarcinoma.

Germline BRCA-mutated metastatic pancreatic adenocarcinoma is an advanced stage IV malignancy arising from the exocrine ductal epithelial cells of the pancreas that has disseminated to distant anatomical sites.

This specific clinical subset occurs in individuals who carry inherited, deleterious or suspected deleterious germline alterations in either the *BRCA1* or *BRCA2* tumor suppressor genes.

Pathophysiologically, loss of functional BRCA proteins impairs homologous recombination repair of DNA double-strand breaks, inducing genomic instability and rendering the tumor selectively vulnerable to DNA-damaging cytotoxic agents and PARP inhibition.

Clinically, it represents an aggressive, highly lethal presentation of pancreatic cancer, typically managed systemically due to widespread metastatic involvement.

Personalize your experience

Follow Germline BRCA-mutated metastatic pancreatic adenocarcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it